GSK3B and neoplasm: Intriguingly, the expression of T334A 53BP1 in SB28 dramatically enhanced response to Olaparib-induced cell killing and tumor control without further effect on PARPi sensitivity with GSK3B inhibition (Figure 11, C–F, and Supplemental Figure 10).